In This Article:
Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose monitoring (“CGM”) sensor compatibility.
The latest development represents a significant step forward in expanding access to its innovative, tubeless Omnipod 5 AID system for more people globally.
PODD Stock’s Likely Trend Following the News
Following the announcement on March 18, PODD’s shares climbed 2% to $265.82 in Tuesday’s trading session. The company’s solid innovation efforts and ongoing expansion of the Omnipod 5 platform are solidifying its market leadership. We expect the market sentiment toward the PODD stock to remain positive surrounding this development.
Insulet has a market capitalization of $18.67 billion at present. Going by the Zacks Consensus Estimate, the company’s earnings are likely to increase 33% in 2025 on an 18.1% improvement in revenues. In the trailing four quarters, it delivered an earnings beat of 27.52%, on average.
About Insulet’s Omnipod 5
Omnipod 5 is the first and only FDA-cleared tubeless AID system indicated for individuals with type 1 and type 2 diabetes. Omnipod 5 system simplifies diabetes management and has shown an improvement in results by removing the need for multiple daily injections (“MDI”) therapy along with automatically adjusting insulin delivery every five minutes using its advanced SmartAdjust technology.
Growing Presence of Insulet’s Omnipod 5
Omnipod 5 was first introduced in the United States in 2022 and has demonstrated strong clinical results with real-world evidence. In 2023, after the successful launch in the U.K. and Germany, Insulet introduced Omnipod 5 in France, one of its largest markets, and the Netherlands in June 2024. In January 2025, Omnipod 5 became available in five more countries, Italy, Denmark, Finland, Norway and Sweden, with both Abbott’s FreeStyle Libre 2 Plus and Dexcom G6 compatibility. Insulet recently expanded sensor integrations to include Dexcom G7 for Omnipod 5 users in the United Kingdom and the Netherlands.
Insulet’s Plans for Omnipod 5’s Expansion
Insulet is anticipating to bring Omnipod 5 to more markets in the upcoming quarters of 2025. The company expects to launch Omnipod 5 in Belgium and Switzerland with Abbott’s FreeStyle Libre 2 Plus, and Dexcom G6 and G7 sensor integrations. In addition, Omnipod 5 will be launched in Canada with Dexcom G6 and G7 sensor compatibility. It will be soon available in five more markets including Israel, Saudi Arabia, the United Arab Emirates, Qatar and Kuwait.